Chinese Journal of Pharmacovigilance ›› 2014, Vol. 11 ›› Issue (9): 561-563.
Previous Articles Next Articles
LIU Wei, LI Xin-lin CHEN Gang, SHEN Lu, DONG Duo, LIU Cui-li, WANG Ya-li
Received:
2014-06-05
Revised:
2016-02-03
Online:
2014-09-08
Published:
2016-03-02
CLC Number:
LIU Wei, LI Xin-lin CHEN Gang, SHEN Lu, DONG Duo, LIU Cui-li, WANG Ya-li. Study on the Evaluation for Quality of Adverse Drug Reaction Reports in China[J]. Chinese Journal of Pharmacovigilance, 2014, 11(9): 561-563.
Add to citation manager EndNote|Ris|BibTeX
[1] CFDA. 药品不良反应报告和监测管理办法[EB/OL].(2014-05-04)[2014-09-02].http://www.cfda.gov.cn/WS01/CL1031/62621.html. [2] CFDA.国家药品不良反应监测年度报告(2013年)[EB/OL].(2014-05-14)[2014-07-31]. http://www.cfda.gov.cn/WS01/CL0078/99794.html. [3] 王晓瑜,杜文民,王宏敏,等. 2005年上海市药品不良反应自发报告质量评价[J]. 中国临床药学杂志,2006,15(5):331-333. [4] 孙骏,徐厚明,李小丽. 江苏省2005年药品不良反应/事件报告表》质量分析[J]. 中国药物警戒,2006,3(4):205- 206. [5] 裴振峨,张俊,邢丽秋,等. 北京市药品不良反应报告体系质量分析[J]. 临床药物治疗杂志,2006,4(3):59- 62. [6] 田月洁,周勇,黄琳,等. 药品不良反应报告质量评价与控制的探讨[J]. 中国药物警戒, 2009,6(2):90-95. [7] 国家药品不良反应监测中心.关于发布《药品不良反应病例报告质量评估指导意见(试行)》的通知[S]. 北京,2009:4. |
[1] | ZHAO Jie, GAO Minge, CHANG Hong, FAN Huixia. Pathogen Distribution, Drug Resistance and Drug Use in Neonates with Necrotizing Enterocolitis Complicated with Sepsis [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 909-913. |
[2] | QI Yujie, WANG Xin, ZHANG Jiahui, MA Enlong, GENG Xingchao. Research Progress in Integration Sites for Cellular and Gene Therapy Products [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 721-727. |
[3] | LI Dong, SONG Yana, WANG Ligang, BIAN Rongrong, ZHAO Yan. Considerations for Establishing National Sentinel Hospitals for Medical Device Adverse Event Monitoring [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 780-785. |
[4] | ZHU Huijuan, REN Jingtian. Safety Risks of Human Rabies Immunoglobulin [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 786-789. |
[5] | LI Qiurong, FU Miaoqing, ZHOU Baishui, LI Cui, XIAO Xiaotong, YU Yuping, DENG Lu. Mining of Real-World ADR Signals Related to Cefradine for Injection in 268 Cases [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 790-793. |
[6] | LI Can, LIU Lehuan, CHEN Xia, QU Jianbo. Pharmacy of Chinese Medicine Compound Preparations Based on Human Experiences [J]. Chinese Journal of Pharmacovigilance, 2025, 22(5): 564-569. |
[7] | YANG Xuyun, SUN Yang, TIAN Chunhua, HU Zengyao. A National Pharmacovigilance Management System in a New Era [J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 276-281. |
[8] | LIU Ying, XIONG Shunyu, XIONG Huiyu, CAI Fei, XU Mengdan, WANG Qing, REN Wei, XU Yan. Methods for Assessment of MAH Compliance with GVP [J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 282-285. |
[9] | ZHU Lan, SHAO Bo, ZHU Yan, DAI Jie, ZHONG Shiqi. Current Progress and Considerations in Updating the Safety Information in Labels of Chinese Traditional Patent Medicines [J]. Chinese Journal of Pharmacovigilance, 2025, 22(2): 188-192. |
[10] | LI Wenlong, JIA Juanjuan, HUANG Haiwei, YAO Jing, ZHANG Chunqing, WANG Yan, ZHANG Hui. Developments and Prospects of Radiopharmaceuticals in China [J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 37-42. |
[11] | SONG Fuyu, CAO Yi. Establishment of Key Performance Indicators for Drug Inspection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(12): 1411-1414. |
[12] | ZHAO Peipei, WEN Baoshu. Regulation of cellular and gene therapies at home and abroad [J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1019-1024. |
[13] | YANG Le, SHAN Lianlian, WANG Yali, YAN Shunhua, ZHOU Gang, CHEN Jia, WEI Feng. Quality standard for licorice of different sources [J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1025-1028. |
[14] | SUN Yixin, NIE Xiaolu, WANG Xiaoling, GUO Peng. Comparative research on active post-marketing drug safety surveillance systems worldwide based on real-world data [J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 892-899. |
[15] | WEI Fenfang, WU Wenyu, LI Limin, TANG Biyu, WU Jianru. Foreign methods for benefit-risk assessment of pharmaceutical products [J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 900-905. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||